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ABSTRACT 
Half of the human genome is made of Transposable Elements (TEs) whose ongoing activity 
continues to impact our genome. LINE-1 (or L1) is an autonomous non-LTR 
retrotransposon in the human genome, comprising 17% of its genomic mass and containing 
an average of 80-100 active L1s per average genome that provide a source of inter-
individual variation. New LINE-1 insertions are thought to accumulate mostly during 
human embyogenesis. Surprisingly, the activity of L1s can further impact the somatic 
human brain genome. However, it is currently unknown whether L1 can retrotranspose in 
other somatic healthy tissues or if L1 mobilization is restricted to Neuronal Precursor Cells 
(NPCs) in the human brain. Here, we took advantage of an engineered L1 
retrotransposition assay to analyze L1 mobilization rates in human mesenchymal (MSCs) 
and hematopoietic (HSCs) somatic stem cells. Notably, we have observed that L1 
expression and engineered retrotransposition is much lower in both MSCs and HSCs when 
compared to NPCs. Remarkably, we have further demonstrated for the first time that 
engineered L1s can retrotranspose efficiently in mature non-dividing neuronal cells. Thus, 
these findings suggest that the degree of somatic mosaicism and the impact of L1 
retrotransposition in the human brain is likely much higher than previously thought.  
 
INTRODUCTION 
Mammalian genomes contain a high number of Transposable Element (TE)-derived sequences, 
and up to 70% of our genome represent TE-derived sequences (de Koning et al. 2011; 
Richardson et al. 2015). Over evolution, the human genome has accumulated millions of TE 
insertions that have shaped its structure and function (Beck et al. 2011; Richardson et al. 2015). 
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The activity of TEs continues to impact the human genome and a fraction of non- LTR 
retrotransposons continue to mobilize in our genome (Mills et al. 2007; Beck et al. 2011; 
Richardson et al. 2015). Approximately half million Long INterspersed Element class 1 (LINE-1 
or L1) retrotransposons comprise almost a fifth of the human genome (Lander et al. 2001; Beck 
et al. 2011; Richardson et al. 2015). Although the great majority of LINE-1s are molecular 
fossils that have lost the ability to mobilize due to the accumulation of mutations and other DNA 
rearrangements, an average human genome contains 80-100 potentially active 
Retrotransposition-Competent L1s (RC-L1s) (Brouha et al. 2003; Beck et al. 2010). LINE-1s are 
non-LTR retrotransposons that mobilize by a “copy and paste” mechanism using an intermediate 
RNA (Luan et al. 1993; Beck et al. 2011; Richardson et al. 2015). RC-L1s are 6 kb-long 
elements and encode two proteins (ORF1p and ORF2p) that are strictly required for 
retrotransposition (Moran et al. 1996). ORF1 codes for an RNA-binding protein with nucleic 
acid chaperone activity (Hohjoh and Singer 1996; Hohjoh and Singer 1997; Martin and Bushman 
2001; Khazina and Weichenrieder 2009) while ORF2 encodes a protein with ENdonuclease (EN) 
and Reverse Transcriptase (RT) activities (Mathias et al. 1991; Feng et al. 1996). 
Retrotransposition starts with the transcription of a full-length RC-L1 mRNA, using an internal 
promoter located in the L1-5’Untranslated region (UTR) (Swergold 1990). The L1 mRNA is 
translated in the cytoplasm (Alisch et al. 2006; Dmitriev et al. 2007) and ORF1 and ORF2 
proteins preferentially bind back to their same encoding mRNA to form a RiboNucleoprotein 
Particle (L1-RNP) (Wei et al. 2001). Numerous host factors are known to interact with L1-RNPs, 
and some of these factors control the rate of retrotransposition. (Goodier et al. 2013; Taylor et al. 
2013; Moldovan and Moran 2015). Studies in transformed cell lines have demonstrated that L1-
RNPs can enter the nucleus without cell division (Kubo et al. 2006), where retrotransposition 
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takes place by a mechanism termed Target Primed Reverse Transcription (TPRT, reviewed in 
(Beck et al. 2011; Richardson et al. 2015; Goodier 2016)). The result is a new L1 insertion that is 
usually 5´truncated and flanked by short Target Site Duplications (TSDs) (Beck et al. 2011; 
Richardson et al. 2015; Goodier 2016).  
RC-L1s continue to impact the germline genome (i.e., the genome that pass to the next 
generation) and new insertions can sporadically act as human germline mutagens (reviewed in 
(Beck et al. 2011; Hancks and Kazazian 2012; Richardson et al. 2015; Goodier 2016)). The use 
of cultured cells, animal models and patient characterization has so far suggested that most de 
novo L1 retrotransposition events in humans accumulate during early embryogenesis (Garcia-
Perez et al. 2007; van den Hurk et al. 2007; Kano et al. 2009; Wissing et al. 2012; Klawitter et al. 
2016). Interestingly, LINE-1 activity is not restricted to the germline and embryonic genomes, 
and new L1 insertions can accumulate in tumors (reviewed in (Carreira et al. 2013)) and in the 
brain (reviewed in (Singer et al. 2010; Richardson et al. 2014a)). Indeed, using a cell-based 
engineered L1-retrotransposition assay, previous studies have demonstrated ongoing L1 
retrotransposition in tumor cells (Moran et al. 1996; Ostertag et al. 2000) and in mammalian 
Neuronal Progenitor Cells (NPCs) (Muotri et al. 2005; Coufal et al. 2009; Muotri et al. 2010; 
Coufal et al. 2011). Additionally, next generation DNA sequencing approaches have 
demonstrated that the human brain is a mosaic of genomes due to ongoing L1 activity (Baillie et 
al. 2011; Evrony et al. 2012; Upton et al. 2015; Erwin et al. 2016).  
The somatic activity of L1s suggest that new L1 insertions might shape the 
structure/function of the human brain genome, although the extent and type of cells that can 
accumulate new L1 insertions in the brain remain largely unexplored. Additionally, it is currently 
unknown whether other adult non-brain somatic stem cells also accommodate the activity of RC-
 Cold Spring Harbor Laboratory Press on March 15, 2017 - Published by genome.cshlp.orgDownloaded from 
 5
L1s.  
 
RESULTS 
L1 expression and engineered retrotransposition in human ectodermal cells. 
To explore L1 expression and retrotransposition in human NPCs, we exploited the 
differentiation potential of human embryonic stem cells (H9-hESCs) (Thomson et al. 1998) to 
obtain homogenous populations of NPCs (Supplemental Fig. 1A). Consistent with previous 
findings (Coufal et al. 2009; Coufal et al. 2011), H9-derived NPCs express canonical neuronal 
markers (Fig. 1E; Supplemental Fig. 1B) and abundant L1 mRNAs (Fig. 1B). These data were 
confirmed using Western-blotting and confocal microscopy analyses (Fig. 1A; Supplemental Fig. 
1C,D). Pluripotent H9-hESCs and Human Foreskin Fibroblasts (HFFs) were used as positive and 
negative controls of L1 expression, respectively (Garcia-Perez et al. 2007; Garcia-Perez et al. 
2010; Wissing et al. 2011; Wissing et al. 2012). Importantly, an engineered retrotransposition 
assay confirmed that NPCs support elevated rates of L1 mobilization (Fig. 1C). In this assay, an 
enhanced green fluorescent protein (EGFP) reporter gene cassette (megfpI (Ostertag et al. 
2000)), interrupted by a backwards intron and inserted in opposite transcriptional orientation into 
the 3’UTR of an RC-L1 (Supplemental Fig. 1E, plasmid 99-gfp-LRE3 (Coufal et al. 2009; 
Garcia-Perez et al. 2010)) is expressed only when the L1 transcript is spliced, reverse 
transcribed, its cDNA inserted in the genome and the EGFP reporter gene expressed from its 
own promoter (Fig. 1C; Supplemental Figure 1E). As a control, an allelic plasmid containing two 
missense mutations in L1-ORF1p (RR261/62AA) failed to retrotranspose in NPCs, as expected 
(Moran et al. 1996; Coufal et al. 2009; Coufal et al. 2011). These data were further confirmed 
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using a PCR-based assay and a set of primers flanking the engineered intron in the megfpI 
cassette (Fig. 1C; Supplemental Fig. 10G; Table 1).  
To support these findings, and to avoid limitations of plasmid transfections, we next took 
advantage of a previously developed adenovirus-retrotransposon hybrid virus (A/RT-pgk-L1RP-
EGFP, herein named Ad-L1, (Kubo et al. 2006)). The hybrid adenovirus contains a human RC-
L1 (L1-RP (Kimberland et al. 1999)) tagged with the megfpI retrotransposition cassette (Ostertag 
et al. 2000); additionally, the Ad-L1 contains an exogenous phosphoglycerate kinase-1 (PGK1) 
promoter to increase L1 expression and to correct for expression differences among transduced 
cell types; finally, the Ad-L1 also contains an independent SV40-driven beta-galactosidase (beta-
gal) expression cassette (Fig. 1D; (Kubo et al. 2006)). Notably, the Ad-L1 allows introduction of 
the L1-reporter into cultured cells by infection, solving difficulties associated to transfection 
(Kubo et al. 2006). Additionally, the beta-gal expression cassette allows controlling infection 
efficiency. Controls revealed efficient transduction and L1 retrotransposition in NPCs (Fig. 1E; 
Supplemental Fig. 2C) and HeLa cells (Supplemental Fig. 2A,B) using the Ad-L1. Thus, these 
data corroborate that hESC-derived NPCs express moderate levels of endogenous L1s (~40% of 
the level detected in hESCs) and can accommodate significant levels of L1 retrotransposition 
(Table 1). 
We next examined L1 expression in other ectodermal-derived cells including 
keratinocytes (KER) and HFFs. KERs are considered multipotent embryonic progenitor cells that 
generate the epidermal barrier as well as hair and nail (Fuchs 2007). Despite their shared 
ontological origin with NPCs, both adult KERs and HFFs express low levels of endogenous L1 
mRNAs, as revealed by RT-qPCR and Western-blot analyses (Fig. 2A,B; Supplemental Fig. 
1D). These data was confirmed by semi-quantitative RT-PCR (Supplemental Fig. 1I). Notably, 
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when we analyzed the DNA-methylation status of L1 human-specific (L1Hs) promoters (Coufal 
et al. 2009; Munoz-Lopez et al. 2012; Wissing et al. 2012), we detected hypermethylated 
promoters in HFFs and KERs when compared to hESCs (Supplemental Fig. 1F,G,H), consistent 
with L1 expression levels. Next, we used the Ad-L1 adenovirus to analyze L1 retrotransposition 
in KERs and HFFs. Despite efficient transduction of both cell types, we observed very low L1 
retrotransposition (Fig. 2C; Supplemental Fig. 2D,E). Thus, these data reveal that not all human 
ectodermal multipotent cells express significant amounts of L1 mRNAs or support L1-
retrotransposition (Table 1). 
 
L1 expression and engineered retrotransposition in multipotent human Mesenchymal Stem 
Cells (MSCs). 
To explore whether L1 expression and retrotransposition is restricted to human 
ectodermal NPCs, we next analyzed L1 expression and retrotransposition in Mesenchymal Stem 
Cells (MSCs). In these assays, we used H9-hESC-derived MSCs (Sanchez et al. 2011) and 
MSCs isolated from adult sources (Bone Marrow (BM), Umbilical Cord (UC) and Adipose 
tissues (ASC)). Notably, using H9-hESCs to differentiate MSCs allowed us to compare between 
different cell types that contain the same genetic background. All MSCs cultured had similar 
fibroblast-like morphology and expressed canonical markers (NT5E (also known as CD73), 
ENG (also known as CD105), THY1 (also known as CD90) and ALCAM (also known as 
CD166) and did not express PTPRC (also known as CD45), CD34, CD19 and SSEA4 (Fig. 3A) 
(Dominici et al. 2006). Controls demonstrated the ability of hESC-derived MSCs to differentiate 
to adipose, osteogenic and chondrocyte lineages, consistent with their multipotent capability 
(Dominici et al. 2006) (Fig. 3G; Supplemental Fig. 4H,I). However, RT-qPCR and semi-
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quantitative RT-PCR experiments revealed that all MSCs tested (despite their origin) expressed 
very low levels of L1 mRNAs (Fig. 3B; Supplemental Fig. 3C,D). These data was confirmed by 
Western-blotting and we observed a low level of L1-ORF1p expression in hESC-derived MSCs 
(Fig. 3C); quantification revealed approximately 5-fold less L1-ORFp when compared to H9-
hESCs (Supplemental Fig. 3A,B). Notably, when we analyzed the methylation status of L1Hs 
promoters, we observed highly methylated L1 promoters in MSCs (Supplemental Fig. 3F,G,H), 
consistent with the low level of L1 mRNA expression detected. Additionally, we also explored 
whether human MSCs grown as mesenspheres, which allows MSCs to preserve better their 
immature phenotype (Isern et al. 2013) (HSPH cells), influence L1 expression. However, under 
our experimental conditions, RT-qPCR revealed that HSPHs express low levels of L1 mRNAs 
(Supplemental Fig. 3E; Table 1).  
We next analyzed L1 retrotransposition in hESC-derived MSCs using the Ad-L1. Despite 
efficient transduction of MSCs as revealed by beta-gal staining, we reproducibly observed a very 
low level of L1 retrotransposition (Fig. 3D). Additional RT-PCR controls revealed that the 
tagged L1 was efficiently expressed in Ad-L1 infected MSCs but that L1 retrotransposition is 
very inefficient in these cells (Fig. 3D; Supplemental Fig. 4D). We confirmed these data using 
the PCR-intron assay (Supplemental Fig. 11G). Further experiments using plasmid 99-gfp-LRE3 
confirmed efficient transfection of MSCs but inefficient L1 retrotransposition (Supplemental 
Figs. 3I,J and 4A,B,C) when compared to HeLa cells transfected in parallel (Supplemental Fig. 
3K). A previous report described fast epigenetic silencing of engineered L1 insertions in human 
pluripotent cells (Garcia-Perez et al. 2010). However, we ruled out epigentic silencing of de novo 
L1 insertions in MSCs by conducting retrotransposition assays with inhibitors of histone 
deacetylases (IHDACs) as described (Garcia-Perez et al. 2010) (Supplemental Fig. 3I). In sum, 
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embryonic and adult multipotent MSCs express low levels of L1 mRNAs and do not 
accommodate efficient L1 retrotransposition (Table 1).  
 
L1 expression and engineered retrotransposition in differentiating human MSCs. 
Because of their multipotent potential, we next tested whether L1 expression and 
retrotransposition changes during MSC differentiation to osteogenic and adipogenic cell types. 
We confirmed robust osteogenic and adipogenic differentiation of hESC-derived MSCs (Fig. 3G; 
Supplemental Fig. 4H). However, we observed no significant changes on L1 expression during 
differentiation, and L1 expression remained very low (Fig. 3E,F; Supplemental Fig. 4E). 
Notably, the promoter of L1Hs elements remained hypermethylated in differentiated MSCs, 
consistent with L1 expression levels (Supplemental Fig. 4F,G). Similarly, when we analyzed 
engineered L1 retrotransposition using the Ad-L1 virus, we reproducibly detected very low 
levels of L1 retrotransposition during MSC differentiation to either adipogenic or osteogenic 
cells, despite their efficient transduction (Fig. 3G; Supplemental Fig. 4H). The intron-PCR assay 
confirmed lack of engineered L1 retrotransposition in differentiating MSCs (see below). In sum, 
pluripotent MSCs and differentiated cell types derived from MSCs are characterized for 
expressing low levels of endogenous L1mRNAs and L1-ORF1p and by accommodating a very 
low level of L1 retrotransposition (Table 1). 
 
L1 expression and engineered retrotransposition in Hematopoietic Stem Cells (HSCs). 
 We next tested L1 expression and retrotransposition in human hematopoietic stem cells 
(HSCs). As above, we isolated HSCs from either pluripotent H9-hESCs or from UC blood 
samples. We used a ficoll and magnetic anti-CD34 microbeads to isolate a homogenous 
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population of multipotent CD34-expressing HSCs from UC blood (>85% purity as revealed by 
FACS analyses; Supplemental Fig. 5A,B). As expected, multipotent CD34+-HSCs could 
differentiate to erythrocyte, monocyte and granulo-monocyte Colony-Forming Units (CFUs) 
when plated in methylcellulose (Supplemental Fig. 5B). When we analyzed L1 mRNA 
expression in CD34+-HSCs, we observed very low levels of L1 expression when compared to 
H9-hESCs, and similar to those detected in HFFs (Fig. 4A), consistent with the hypermethylation 
status of L1Hs promoters in these cells (Fig. 4B; Supplemental Fig. 5D,E). These data was 
confirmed by semi-quantitative RT-PCR (Supplemental Fig. 5C). Additionally, when we 
analyzed Ad-L1 retrotransposition, we reproducibly detected a very low level of L1 
retrotransposition (Fig. 4C), despite efficient Ad-L1 transduction (Supplemental Fig. 11G). Thus, 
CD34+-HSCs express low levels of endogenous L1 mRNAs and support very low levels of L1 
retrotransposition (Table 1).  
 To corroborate these findings, we next used H9-hESCs and two differentiation protocols 
to analyze L1 expression/retrotransposition in more primitive HSCs. We used an Embryoid Body 
(EB) protocol (Chadwick et al. 2003) to isolate hemogenic precursors with hemangioblast 
properties (CD45negPFVs population: CD34+, PTPRC (also known as CD45)- PECAM1 (also 
known as CD31)+, CDH5 (also known as CD144)+, and KDR (also known as FLK1)+) and 
immature HSCs (CD45+ population: CD34+, PTPRC- and PECAM1+) (Fig. 4D; Supplemental 
Fig. 5F). However, we detected very low levels of L1 mRNAs in both CD45negPFVs and 
CD45+ populations (Fig. 4E). Notably, as observed with UC–derived CD34+-HSCs, we 
reproducibly detected very low levels of engineered L1 retrotransposition using the Ad-L1 virus 
in these cells (Fig. 4F; Table 1)).  
 Cold Spring Harbor Laboratory Press on March 15, 2017 - Published by genome.cshlp.orgDownloaded from 
 11
 Next, we used a stroma cell-based differentiation protocol (Choi et al. 2011) and mouse 
OP9 BM-stromal cells to differentiate CD45negPFV and CD45+ populations from H9-hESCs 
(Fig. 4G; Supplemental Fig. 6A,B). However, as observed with the EB-based method, we 
detected a very low level of L1 mRNA expression in these cells (Supplemental Figure 6C) and 
very low levels of L1 retrotransposition in CD45negPFV cells despite efficient Ad-L1 
transduction (Fig. 4H). Consistently, the low level of L1 mRNA expression parallels the DNA-
hypermethylation status of the L1Hs promoter in CD45negPFV and CD45+ populations 
(Supplemental Fig. 5G,H). Thus, different populations of human HSCs characteristically express 
low levels of endogenous L1 mRNAs and support a very low level of L1 retrotransposition 
(Table 1). 
 
L1 expression and engineered retrotransposition in human mature neuronal cells.  
 Due to the apparent restriction of L1 expression/retrotransposition to NPCs, we next 
exploited the Ad-L1 vector to analyze retrotransposition in mature neuronal cells, which are the 
most abundant cell-type in the human brain (Tang et al. 2001). To do that, we derived mature 
neuronal cells from H9-hESC-derived NPCs using established protocols (Muotri et al. 2005; 
Coufal et al. 2009; Muotri et al. 2010; Coufal et al. 2011). Indeed, after 31 days of NPC 
differentiation, we routinely obtained a population of cells expressing pan-neuronal markers 
including RBFOX3 (also known as NeuN), TUBB3, MAP2 and Synapsin I (Supplemental Figs. 
7A,B; 9C). With this protocol, we routinely obtained homogenous populations of mature 
neuronal cells expressing TUBB3 in 80-90% of cells. We also identified minor populations of 
neuronal cells expressing subtype-specific markers including TH (tyrosine hydroxylase), GABA 
(gamma-aminobutyric acid) and CHAT (choline acetyltransferase) (Supplemental Fig. 7B). 
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Using terminally differentiated neuronal-enriched populations of cells, we next analyzed L1 
expression and retrotransposition. Intriguingly, we reproducibly detected a moderately higher 
level of L1 mRNA expression in neurons (~25% of levels detected in H9-hESCs) and slightly 
higher than that detected in HFFs (Fig. 5A; reaching statistical significance, Supplemental Fig. 
8C). However, L1 mRNA expression levels in differentiated neuronal cells are lower than that 
detected in NPCs and hESCs (Figs. 1B; 5A). These data were confirmed by Western-blot 
analyses (Fig. 5B; Supplemental Fig. 8A). Overall, mature neuronal cells express detectable 
levels of L1 mRNAs and L1-ORF1p at levels moderately higher than those detected in HFFs, 
MSCs and HSCs (Table 1). DNA-methylation analyses revealed that L1Hs promoters are heavily 
methylated in differentiated neurons (Supplemental Fig. 8D). Next, we analysed L1 
retrotransposition in in mature non-dividing neuronal cells using Ad-L1. To do that, and because 
L1 retrotransposition is very efficient in undifferentiated NPCs (Fig. 1), we added 5-Bromo-2’-
deoxyuridine (BrdU) to the culture media together with the Ad-L1, to confirm that 
retrotransposition was occurring in terminally differentiated non-dividing neuronal cells (i.e., L1-
EGFP-expressing cells that do not stain with anti-BrdU; Fig. 5C). Thus, we added BrdU and Ad-
L1 at different time points during the 31-day long NPC-differentiation protocol, and analyzed L1 
retrotransposition by confocal microscopy using anti-BrdU and anti-EGFP antibodies and an 
optimized protocol (Supplemental Fig. 9A). Control microscopy analyses revealed that there was 
a drastic reduction in BrdU incorporation as NPCs differentiate (Supplemental Fig. 9B,D). 
Indeed, the rate of BrdU labelling is <0.9% at day 31 post-differentiation, and BrdU labelling is 
detected in low-abundant cells that do not express TUBB3 (Supplemental Fig. 9C). When NPCs 
were infected at day 0 of the differentiation protocol, we detected high levels of L1-
EGFP/BrdU/NES-positive cells, as expected  (Figs. 1; 5D, d0 panel). PCR-controls using a set of 
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primers in the EGFP retrotransposition cassette confirmed efficient retrotransposition in NPCs 
infected at day 0 (Fig. 5E). When differentiated NPCs were infected at day 5, we detected fewer 
L1-EGFP/BrdU-positive cells; notably, L1-EGFP/BrdU-positive cells did not express the 
neuronal marker TUBB3 (Fig. 5D, d5 panel) and we speculate that these L1 retrotransposition 
events could have occurred in non-differentiated NPCs present in the culture at the time of Ad-
L1 infection. Similar data was obtained when the Ad-L1/BrdU was added at day 10 or 15 after 
the initiation of NPC differentiation (Supplemental Fig. 9E). When the Ad-L1/BrdU was added 
at day 25 or 31 post-initiation of NPC differentiation, the level of BrdU incorporation observed 
was less than 1% and we reproducibly observed high levels of TUBB3 expressing cells; 
however, we failed to detect L1-EGFP expressing cells (Fig. 5D, d31 panels). Beta-gal control 
staining experiments revealed efficient Ad-L1 transduction in differentiating NPCs at day 0, 5 
and 31 (Supplemental Fig. 8B), suggesting efficient transduction but low retrotransposition 
levels in non-dividing mature neuronal. Intriguingly however, PCR assays using primers 
flanking the intron in the megfpI cassette revealed the presence of spliced (retrotransposition) 
products in NPCs infected with the Ad-L1 at day 31, suggesting ongoing L1 retrotransposition in 
mature neuronal cells but an inability to express the retrotransposed EGFP reporter (Fig. 5E, 
hESC-NPCs d31 AdL1 lane). Sanger DNA sequencing controls revealed that the amplified 
EGFP product at day 31 corresponded to a bona fide spliced EGFP retrotransposition product, 
marked by a unique engineered Pvu II site in the EGFP gene.  
We next tested whether lack of expression from the inserted L1-EGFP cassette in mature 
neuronal cells is caused by epigenetic silencing of de novo retrotransposition events (Garcia-
Perez et al. 2010). However, neither treatment with IHDACs (trichostatin A, sodium butyrate or 
valproic acid) at day 5 post-infection (i.e., d36 since the initiation of differentiation) or treatment 
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with the de novo methylation inhibitor 5-azacytidine for 5 days led to reactivation of L1-EGFP 
expression (Supplemental Fig. 9F,G). These data suggest that de novo L1 insertions in mature 
neuronal cells are not silenced by histone modifications as described in pluripotent embryonic 
cells (Garcia-Perez et al. 2010). However, it is likely that the immediate early cytomegalovirus 
(CMV) promoter used to drive EGFP expression from the retrotransposed reporter in Ad-L1 
(Ostertag et al. 2000; Kubo et al. 2006) fails to efficiently express EGFP in cultured mature 
neuronal cells, at least under our experimental conditions. Consistently, there are numerous 
reports suggesting that the CMV promoter is not pan-active in neuronal cells (see (Fritschy et al. 
1996; van den Pol and Ghosh 1998)), consistent with lack of L1-EGFP expression in these cells 
despite efficient Ad-L1 retrotransposition. To test this hypothesis, we generated plasmid DNA 
99-gfp-LRE3-UB* containing an RC-L1 (LRE3 (Brouha et al. 2002)) tagged with a modified 
megfpI cassette where the CMV promoter that drives EGFP expression was replaced by a 
ubiquitously expressed human UBC promoter (Fig. 6A). Notably, the UBC promoter used in this 
construct is characterized for its enrichment in acetylated H3K27. Controls in HeLa revealed 
efficient engineered L1 retrotransposition with plasmid 99-gfp-LRE3-UB* (Supplemental Fig. 
10A,B). Next, we used either nucleofection or a calcium based protocol (Methods) to transfect 
plasmid 99-gfp-LRE3-UB* in differentiating NPCs at day 31, in the presence of BrdU. 
Remarkably, and despite reduced efficiency of transfection in neuronal cells at day 31, we 
readily detected cells expressing mature neuronal markers (MAP2 or TUBB3) and the L1-EGFP 
retrotransposed cassette (i.e., L1-EGFP), but that did not stain positive for BrdU, suggesting 
efficient engineered L1 retrotransposition in non-dividing mature neuronal cells (Fig. 6A; 
Supplemental Fig. 10C). Additional controls confirmed specificity of the staining and lack of 
retrotransposition from an allelic mutant L1 construct (RR261/62AA mutation, plasmid 99-gfp-
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JM111-UB*) in non-dividing mature neurons (Supplemental Fig. 10D, E). To further confirm 
these findings, transfected hESC-NPCs-d31 cells were analyzed using the PCR intron assay 
(Ostertag et al. 2000). Notably, we observed amplification of a product corresponding to the 
transfected vector in all samples (i.e., cells transfected with an active (99-gfp-LRE3-UB*) or 
inactive (99-gfp-JM111-UB*) L1 construct); importantly, we only amplified the spliced EGFP 
(i.e., retrotransposition product) in neurons transfected with the active LINE-1 and not in cells 
transfected with the inactive allelic LINE-1 (Supplemental Fig. 10F). As expected, similar results 
were observed in transfected hESC-NPCs at day 0 (Supplemental Fig. 10G). In sum, these data 
reveal that engineered human L1s driven from its own promoter can efficiently retrotranspose in 
mature non-diving neuronal cells (Table 1). 
 
Efficient engineered L1 retrotransposition in human mature neuronal cells.  
 Due to the toxicity of mature neuronal cells upon DNA-transfection, and in order to 
quantify the level of engineered L1 retrotransposition, we next used the Ad-L1 and a specific set 
of qPCR primers to the spliced EGFP retrotransposed reporter cassette (retrotransposition 
product) (Del Re et al. 2010) to calculate the efficiency of retrotransposition in neurons. 
Additionally, we designed and validated qPCR primers for beta-gal, allowing us to calculate the 
number of EGFP insertions per infected cell (Supplemental Fig. 11A). As a copy number control 
in qPCRs, we used a previously characterized cell line containing two L1-EGFP insertions (pk87 
cells, Supplemental Fig. 11B; (Garcia-Perez et al. 2010)). Using qPCR, we determined that the 
copy number of L1-EGFP sequences accumulated in HeLa cells is roughly 10-fold higher than in 
NPCs, at least using the Ad-L1 (Supplemental Fig. 11C,D,E). Additionally, we further validated 
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and used this qPCR assay to confirm that engineered L1 retrotransposition is extremely low in 
Ad-L1 infected HSCs and MSCs (Supplemental Fig. 11G,I; Table 1)).  
We next compared the number of L1-EGFP insertions detected in differentiating NPCs 
that were infected at day 0 (i.e., multipotent NPCs) and at day 31 (i.e., mature neuronal cells). 
We also measured the proliferation values of differentiating NPCs at day 0 and 31 to control for 
different cell division rates, which could led to amplification of L1-EGFP insertions in dividing 
cells (Supplemental Fig. 11F,H). Thus, we used proliferation values to correct the accumulated 
number of L1-EGFP sequences in each cell type. Remarkably, we observed that the amount of 
L1-EGFP copies detected in mature neuronal cells was approximately 6-fold higher than in 
multipotent NPCs (Fig. 6B), suggesting very efficient engineered L1 retrotransposition, or more 
insertions per cell, in differentiated NPCs infected at day 31.  
Next, and to rule out that a fraction of detected L1-EGFP sequences corresponded to L1 
retrotransposition events accumulated in non-neuronal cells (i.e., low abundant cells present in 
the differentiating NPC culture at day 31), we isolated RBFOX3-expressing cells by FACS-
sorting and then conducted the qPCR (Fig. 6C). Briefly, differentiated NPCs at day 31 were 
infected with the Ad-L1 and 4 days later mature neuronal cells were FACS-sorted using 
RBFOX3 (also known as NeuN), a marker of mature post-mitotic neurons. Consistently, >80% 
of cells expressed RBFOX3 at day 35 after initiation of NPC differentiation (Fig. 6C). Next, the 
qPCR was done on genomic DNAs isolated from RBFOX3-sorted cells. Control PCRs indicated 
efficient L1 retrotransposition in RBFOX3-sorted cells (Fig. 6D) and qPCR revealed that the 
copy number of L1-EGFP in RBFOX3-sorted cells is almost identical to the level detected in 
non-sorted cells (Fig. 6E). These data suggest that the majority of L1-EGFP sequences (i.e., 
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retrotransposition) accumulate in RBFOX3-expressing cells. In sum, these data indicate that L1 
retrotransposition is very efficient in RBFOX3-expressing mature neuronal cells.  
 
DISCUSSION 
In this study, we have compared L1 expression and engineered L1 retrotransposition among 
different human cell types differentiated from the same hESC line (H9), ensuring that all cell 
types analyzed have the same genetic background. Additionally, we have further explored L1 
expression and retrotransposition in KERs, HFFs, MSCs and HSCs derived from adult sources 
(see Table). Finally, we have exploited a helper adenovirus-based vector (Ad-L1) to overcome 
inherent limitations to DNA-transfection experiments (Villa-Diaz et al. 2010). Indeed, the Ad-L1 
system allows introduction of the L1-reporter into cultured cells by infection, solving difficulties 
in transfecting different cell types (Kubo et al. 2006). Using this design, our data indicate that the 
somatic retrotransposition of L1s is not a generic property of all somatic stem cell types of the 
human body. On the contrary, our data suggest that L1 expression and the capability to support 
L1 retrotransposition is restricted to a minor population of neuronal cells with multipotent 
characteristics. Indeed, these data are in agreement with previous reports that analyzed L1 
expression in several somatic human tissues, revealing detectable but low L1 expression in 
stomach, esophagus, prostate and heart muscle, while expression in the adrenal gland, kidney, 
spleen and cervix was below the detection limit (Faulkner et al. 2009; Belancio et al. 2010). 
Regarding expression of L1 mRNAs, we have observed a very good correlation between the 
DNA-methylation status of the L1Hs promoter and the expression level of L1 mRNAs detected, 
consistent with DNA-methylation being a main host factor restricting human retrotransposition 
in somatic cells (Bestor 2003; Coufal et al. 2009). Using the Ad-L1 as well as conventional 
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plasmid-based retrotransposition assays, we have demonstrated that L1 retrotransposition is very 
low in KERs, HFFs, MSCs and HSCs when compared with isogenic NPCs. Our data further 
demonstrated that de novo L1 insertions in KERs, HFFs, MSCs and HSCs are not strongly 
silenced by histone modifications as described for human embryonic carcinoma cells (Garcia-
Perez et al. 2010). Conventional intron-PCR assays, as well as a qPCR-based assay that quantify 
infected cells (beta-gal copy number) and L1 insertions (spliced EGFP copy number), have 
further demonstrated that retrotransposition is extremely low in MSCs and HSCs when compared 
with isogenic NPCs. Although we do not know why we observed very low L1 retrotransposition 
in KERs, HFFs, MSCs and HSCs compared with NPCs, we speculate that differential expression 
of host factors that are required for efficient retrotransposition (Goodier et al. 2013; Taylor et al. 
2013; Moldovan and Moran 2015) may explain the observed differences in retrotransposition 
rates among cells. However, recent data acquired on human tumors suggest that selected somatic 
tissues may normally tolerate a low level of somatic LINE-1 retrotransposition, as recently 
described in normal gastrointestinal tissues (Ewing et al. 2015). Indeed, it is also possible that the 
differential expression of restriction factors may affect the rate of L1 retrotransposition in a 
defined cell type. Intriguingly, exploiting publically available RNA-seq data from ENCODE 
(The ENCODE Project Consortium, 2012) revealed that HSCs express 3-fold more APOBEC3A 
mRNA than hESC-derived NPCs (Supplemental Fig. 12); as APOBEC3A is known to inhibit 
LINE-1, we speculate that APOBEC3A expression in HSCs might explain the low level of LINE-
1 retrotransposition detected in HSCs (Table 1). However, we also observed that the difference 
in gene expression for APOBEC3A among HSCs and hESCs is not statistically significant, 
suggesting that additional host factors might influence and regulate LINE-1 retrotransposition in 
HSCs. Clearly, future studies are required to distinguish between these possibilities.  
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We have additionally tested L1 expression and engineered L1 retrotransposition in mature 
neuronal cells, which are orders of magnitude more abundant than NPCs in the human brain. 
Notably, our data demonstrate that engineered L1 retrotransposition can take place in non-
dividing mature neuronal cells. The use of the beta-gal/EGFP qPCR assay strongly suggests that 
retrotransposition in mature non-dividing neuronal cells might be even more efficient than in 
NPCs. That said, there are caveats to these calculations, as we are: i) comparing dividing cells vs 
non-dividing cells and ii) using a plasmid-based reporter system to quantify number of 
insertions. Thus, our rate of engineered L1 retrotransposition in mature neuronal cells might not 
be an absolute number. However, the rate of engineered L1 retrotransposition in mature neuronal 
cells detected in this study suggests that retrotransposition in the human brain might be much 
more abundant than previously anticipated (Evrony et al. 2012; Erwin et al. 2016). Indeed, our in 
vitro data is in agreement with a recent study where genomic mosaicism due to retrotransposition 
in the human brain was explored at the single cell level (Upton et al. 2015).  
In sum, here we demonstrate that retrotransposition can occur with high efficiency in mature 
neuronal cells. However, it remains to be determined whether all mature neuronal cell types have 
the same capability to support L1 retrotransposition or whether aging affects the rate of 
endogenous L1 retrotransposition in neurons. Indeed, we speculate that L1 retrotransposition 
might be very efficient in the human brain, raising the possibility that each neuronal cell in our 
brain may contain a unique genome, characterized by its own unique set of retrotransposon 
somatic insertions. This concept has implications for both the development of neuronal plasticity 
and brain pathology. We further speculate that misregulation of L1 expression, already elevated 
in the brain, could be influenced by natural polymorphisms on host restriction factors and this 
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could alter the impact of retrotransposon-induced changes in neuronal genomes, and maybe the 
possibility of developing a neurological disorder. 
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METHODS  
Cell line culturing 
Standard procedures were used to culture and derivate all cellular types used in this study (see 
Supplemental Methods for a detailed description).  
Neuronal, Mesenchymal and Hematopoietic differentiation assays.  
NPCs, MSCs, and HSCs were obtained from H9-hESCs using established methods (Chadwick et 
al. 2003; Wang 2006; Wang et al. 2006; Vodyanik and Slukvin 2007; Ji et al. 2008; Coufal et al. 
2009; Raya et al. 2009; Muotri et al. 2010; Choi et al. 2011; Sanchez et al. 2011). See 
Supplemental Methods for additional details and quality controls used to confirm the identity of 
derived somatic cells.  
Plasmid constructs. 
All plasmids used in this study have been previously described (Alisch et al. 2006; Garcia-Perez 
et al. 2007; Coufal et al. 2009; Garcia-Perez et al. 2010; Richardson et al. 2014b) except: 
p99-gfp-LRE3-UB*: is a derivative of plasmid p99-gfp-LRE3 where the CMV promoter that 
drives expression of EGFP in the megfpI cassette has been replaced by the human UBC promoter 
(nucleotides 125398319-125399530 of human chromosome 12).  
p99-gfp-JM111-UB*: is a derivative of plasmid p99-gfp-JM111 where the CMV promoter that 
drives expression of EGFP in the megfpI cassette has been replaced by the human UBC promoter 
(nucleotides 125398319-125399530 of human chromosome 12).  
Transfection of cultured cells and retrotransposition assays using plasmids. 
Retrotransposition assays in HeLa-JVM cells were conducted as described (Wei et al. 2000). H9-
hESCs, MSCs, hESC-derived MSCs, hESC-derived NPCs, MSCs and HFFs were transfected by 
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Nucleofection (Amaxa) as previously described (Garcia-Perez et al. 2007; Coufal et al. 2009; 
Wissing et al. 2012). hESCs-derived neurons were transfected using the AD1 Primary Cell 4D-
Nucleofector Y Kit (Lonza) and program EH-158. Briefly, 1x105 hESC-derived NPCs were 
differentiated during 31 days (Coufal et al. 2009; Muotri et al. 2010) and next adhered mature 
neuronal cells were transfected with 15μg of the indicated plasmid using a nucleofection in the 
presence of 4μM BrdU (Sigma). After transfection, hESC-derived neurons were fed with a 1:1 
mixture of the collected NB-conditioned media and fresh NB media supplemented with 10μM 
iRock (Y-27632, Sisma) and 4μM BrdU during 5 days. L1-EGFP-expression was next 
monitored by immunostaining. Additional transfection experiments of hESC-derived neurons 
were conducted using a CalPhos Mammalian Transfection Kit (Clontech) and following the 
manufacturer´s instructions using 1μg of each plasmid DNA in 24-well tissue culture plates 
containing differentiated neurons at day 31. 
Ad-L1 construct, virus preparation and transduction of cultured cells. 
The helper dependent adenovirus construct A/RT-pgk-L1RP-EGFP has been previously 
described (Soifer et al. 2001; Kubo et al. 2006) and was prepared as described (Kubo et al. 2006; 
Palmer and Ng 2008). All cell types used were transduced as described (Kubo et al. 2006). In 
this study, we used three batches of Ad-L1, averaging approximately 7.6x1012 viral particles/ml. 
Immunocytochemistry analyses. 
Immunocytochemistry assays were conducted as described (Garcia-Perez et al. 2007; Coufal et 
al. 2009; Wissing et al. 2012) and slides were imaged using a Zeiss LSM-710 confocal 
microscope (Leica) unless otherwise indicated. In experiments conducted with BrdU, we first 
stained with the indicated antibody and then conducted the BrdU labelling. Antibodies and 
dilutions used can be found in the Supplemental Methods. 
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Fluorescence-activated cell sorting analyses of RBFOX3 expressing cells. 
FACS sorting assays were conducted as previously described (Upton et al. 2015), 31 days after 
initiation of NPC differentiation.  
Genomic DNA isolation, conventional PCR and Quantitative PCR assays. 
We used standard procedures to isolate DNA and in conventional PCRs. qPCRs were performed 
using a StepOne Real-Time PCR System (Applied Biosystems) and GoTaq qPCR MasterMix 
(Promega). Quantitative PCR reactions were carried out using 40 ng of genomic DNA. To 
minimize calculation errors, in each qPCR we determined the copy number of the 5S ribosomal 
RNA gene, as there are 47 copies in the human genome (Muotri et al. 2010). To calculate the 
copy number of L1-EGFP sequences, we validated and used qPCR primers from (Giorgi et al. 
2011); in calculations, we considered that a normal dipliod cell contains 6.6pg of gDNA (Coufal 
et al. 2009). Results are shown as the number of L1-EGFP copies per every 100 cells. To 
compare insertion rates between different samples, we normalized L1-EGFP copy number values 
obtained with qPCR primers directed to: the SV40 sequence present in all DNA constructs (in 
plasmid transfection experiments) or to the beta-gal sequence (in Ad-L1 transduction 
experiments). Primers used are listed in Supplemental Table S1.  
RNA extraction and LINE-1 expression analyses by RT-qPCR and semi-quantitative RT-PCR. 
Standard procedures were used to isolate RNA and RT-qPCRs were conduced as described 
(Munoz-Lopez et al. 2012). In semi-quantitative RT-PCR experiments, we used a previously 
described protocol (Garcia-Perez et al. 2007).  
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Whole Cell Extract (WCE) and Ribonucleoprotein particle (RNP) isolation and Western-blot 
analyses. 
Whole cell extracts (WCE) or L1-ribonucleoprotein particle (RNP) preparations derived from the 
indicated cell type were prepared as described (Garcia-Perez et al. 2007; Garcia-Perez et al. 
2010; Munoz-Lopez et al. 2012). Antibodies and dilutions used can be found in the 
Supplemental Methods. 
L1 promoter methylation studies. 
Bisulfite analyses were performed as previously described (Coufal et al. 2009; Munoz-Lopez et 
al. 2012; Wissing et al. 2012).   
Cell proliferation analyses. 
To quantify cell proliferation in NPCs during neuronal differentiation, 30 randomly captured 
fields were acquired at d0, d15 and d31. BrdU positive cells were quantified and normalized to 
DAPI staining.  
Gene expression analyses using ENCODE data 
Using ENCODE data (The ENCODE Project Consortium, 2012), we analyzed expression of host 
factors known to interact (Goodier et al. 2013; Taylor et al. 2013; Moldovan and Moran 2015) or 
to regulate LINE-1 retrotranspositon (Beck et al. 2011; Richardson et al. 2014a; Richardson et al. 
2014b; Goodier 2016) in: fibroblasts, HSCs H7-hESCs, MSCs and NPCs derived from H9-
hESCs. Sequencing data used is avalaible under accession numbers: ENCSR000CUH, 
ENCSR000CUA, ENCSR490SQH, ENCSR000CTZ and ENCSR244ISQ. Briefly, we explored 
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gene expression differences and selected those genes whose expression levels were significantly 
changed (Rapaport et al. 2013).  
Statistical analyses. 
Ordinary one-way ANOVA was used to compare three or more groups. The Tukey method was 
used for post-test analysis. Student’s t-test was applied to compare two groups. p < 0.05 was 
considered significant in all analyses. 
DATA ACCESS 
Bisulfite Sanger sequencing traces have been submitted to NCBI GenBank 
(https://www.ncbi.nlm.nih.gov/genbank/) under accession numbers: H9-hESCs (KY120517 - 
KY120529), MSCs (KY120530 - KY120546 and KY120585 - KY120598), MSCs differentiated 
to osteogenic cells at day 8 (KY120547 - KY120566) and 15 (KY120567 - KY120584), MSCs 
differentiated to adipose cells at day 10 (KY120599 - KY120620) and 21 (KY120621 - 
KY120632), UC-derived CD34+HSCs (KY120633 - KY120650), HFFs (KY120651 - 
KY120670), hESC-derived CD45+ HSCs (OP9 method, KY120671 - KY120688), hESC-
derived CD45negPFV HSCs (OP9 method, KY120689 - KY120706), KER (KY120707 - 
KY120718) and hESC-derived NPCs differentiated at day 31 (KY120719 - KY120734). 
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FIGURE LEGENDS 
Fig. 1. LINE-1 retrotransposition in human neuronal progenitor cells. (A) Confocal analyses 
of L1-ORF1p expression in H9-hESC (top panel) and H9-hESC-derived NPCs (bottom panel). A 
merged image of nuclear DNA stained with DAPI (blue) and L1-ORF1p staining (green) is 
shown. An enlargement of a portion of the image is shown at the right. Scale bars: 10 μm. (B) 
L1Hs mRNA expression analyses by RT-qPCR. Shown is a cartoon of an active L1Hs element 
where the relative positions of the 5´UTR, ORF1, ORF2 and 3´UTR sequences are indicated. 
Also indicated is the relative position of the primer pair used to analyze L1 expression (N-51 
pair). The numbering refers to the nucleotide sequence of L1.3 (Sassaman et al. 1997). The bar 
graph shows expression data in the indicated sample (n=3 biological replicas). The expression 
level of H9-hESCs was designated 1 for comparison. Also indicated is the significance of the 
statistical method applied (One-way ANOVA with Tukey, p value 0.0257 and 0.0072) and 
standard error of the mean (SEM; see Methods). (C) Representative retrotransposition results in 
hESC-derived NPCs 7 days post-transfection using plasmid 99-gfp-LRE3 (see Supplemental Fig. 
1E). Shown is a FACS histogram plot (SSC-A vs EGFP, the percentage of EGFP-expressing 
cells is indicated, in triplicate) and a merged image (bright field/EGFP) of transfected NPCs with 
plasmid 99-gfp-LRE3. The rightmost panel contains results from the PCR intron assay. pk87 
cells (Garcia-Perez et al. 2010) were used as a positive amplification control of spliced L1-
EGFP. The amplification of a portion of the SV40 polyadenylation sequence was used as a 
control (present in the transfected plasmid, black lollipop in Supplemental Fig. 1E)). (D) 
Rationale of the retrotransposition assay using the Ad-L1 virus. Grey arrows: exogenous 
promoters (PGK1, upstream tagged L1; SV40, beta-gal: CMV, EGFP); blue box: independent 
beta-gal expression cassette; Ad-ITR, inverted terminal repeats of human adenovirus type 5;ψ, 
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packaging signal. With this configuration, expression of EGFP can only be activated after a 
round of retrotransposition (see Supplemental Figure 1E). (E) Representative retrotransposition 
assays using the Ad-L1 in hESC-derived NPCs. Shown is a merged image of Ad-L1-infected 
NPCs analyzed 3 days after infection and stained with antibodies against NES (pink) and EGFP 
(green); nuclear DNA was stained with DAPI (blue). The left side contains the captured images 
used in the merged image. White bars, 5 μm.  
Fig. 2. LINE-1 retrotransposition in human KERs and foreskin fibroblasts. (A) L1Hs 
mRNA expression analyses by RT-qPCR following the nomenclature and method described in 
Figure 1B. The graph shows expression data in the indicated sample and standard error of the 
mean (SEM, n=2 biological replicas). One-way ANOVA with Tukey was used (p value 0.0025 
and 0.0040). (B) Western-blot analyses of L1-ORF1p in the indicated cell type (above each 
lane). Beta actin was used as a loading control. (C) Representative retrotransposition data using 
the Ad-L1 vector in the indicated cell type (7 days post infection). Below the cartoon of Ad-L1, 
shown are bright field images of each cell type and representative FACS histograms (the 
percentage of EGFP-expressing cells is indicated, triplicate). Only H9-hESCs accommodated 
detectable levels of Ad-L1 retrotransposition. 
Fig. 3. LINE-1 retrotransposition in mesenchymal stem cells. (A) Representative bright field 
images of cultured MSCs isolated from the indicated tissue/cell type. The right panel shows 
FACS histograms acquired in pooled MSCs for: NT5E, ENG, THY1, ALCAM, PTPRC, CD34, 
CD19 and SSEA4. (B) L1Hs mRNA expression analyses by RT-qPCR in MSCs. The graph 
shows expression data in the indicated sample (n= 3 biological replicas), the SEM and the 
significance of the statistical method (One-way ANOVA with Tukey, p value <0.0001). (C) 
Western-blot analyses of L1-ORF1p in the indicated cell type (above each lane). Beta actin is 
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used as a loading control. (D) L1-retrotransposition in MSCs using Ad-L1. Shown is an image 
from a representative infection of MSCs with Ad-L1 and stained for beta-gal 3 days post-
infection. An enlarged region is also shown in the bottom-right corner. To the right, RT-PCR 
analyses for EGFP and GAPDH on the indicated cell type. Cells were either infected (Ad-L1 
lanes) or incubated with 1x PBS (non-labeled lanes). The right-most panel shows a 
representative FACS histogram acquired from Ad-L1 infected MSCs 7 days post-infection. The 
percentage of EGFP-expressing cells is indicated as determined in triplicate. (E) L1Hs mRNA 
expression analysis in differentiating MSCs as measured by RT-qPCR (SEM is indicated; n=2 
biological replicas). Statistical method applied is one-way ANOVA with Tukey, p value < 
0.0001. (F) Western-blot analyses of L1-ORF1p expression in the indicated cell type (above 
each lane). Beta actin was used as a loading control. (G) L1-retrotransposition in differentiating 
MSCs using Ad-L1. The left side shows representative images of Oil Red O staining at the 
indicated time after the initiation of MSC differentiation. The right side contains representative 
FACS histograms that indicate the percentage of EGFP-expressing (triplicate) at the indicated 
time. 
Fig. 4. LINE-1 retrotransposition in Hematopoietic stem cells. (A) L1Hs mRNA expression 
analysis in HSCs-CD34+ cells isolated from UC blood as measured by RT-qPCR (n=3 biological 
replicas). Also indicated is the p value (0.0047, One-way ANOVA with Tukey) of the 
comparisons and the SEM. (B) L1Hs promoter methylation in HSCs-CD34+ as measured by 
bisulfite-PCR assays. The graph shows the percentage of methylation detected in the indicated 
sample and the SEM. Also indicated is the p value of the comparisons (p<0.0001 or not 
significant (n.s.), one-way ANOVA with Tukey). (C) L1-retrotransposition in CD34-expressing 
HSCs using the Ad-L1 virus. Below a cartoon of the Ad-L1 is shown a representative FACS 
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histogram acquired 4 days post-infection. The percentage of EGFP-expressing cells is indicated 
within the histogram as determined in triplicate. (D) Scheme of the EB-based protocol to 
differentiate HSCs from hESCs. CD45+ and CD45negPFV populations are pictured using 
yellow and orange spheres. Black spheres, remaining cells. To the right is shown a FACS 
analysis of EBs after the differentiation protocol (PTPRC vs PECAM1). Below are shown 
representative images of the three identified populations. REB, remaining cells; white bars, 20 
μm. (E) L1Hs mRNA expression analysis in CD45+ and CD45negPFV populations as measured 
by RT-qPCR (n=2 biological replicas). The SEM and p value of the comparisons (0.0138, 
0.0152, One-way ANOVA with Tukey) are indicated. (F) L1-retrotransposition in CD45+ and 
CD45negPFV populations using  Ad-L1. Below a cartoon of the Ad-L1 shown are representative 
FACS histograms acquired 4 days post-infection (CD45+ (right panel); CD45negPFV (left 
panel)). The percentage of EGFP-expressing cells is indicated within the histogram as 
determined in duplicate. (G) Scheme of the OP9-based protocol to differentiate HSCs from 
hESCs. The right side shows a representative histogram  (PTPRC vs PECAM1) 8 days after 
initiation of OP9 co-culture. (H) L1-retrotransposition in the CD45negPFV population isolated 
using the OP9 method. Representative FACS histogram (SSC-A vs L1-EGFP) acquired 4 days 
post-infection. Also indicated is the percentage of EGFP-expressing cells as determined in 
triplicate.  
Fig. 5. LINE-1 expression and retrotransposition in differentiating NPCs. (A) L1Hs mRNA 
expression analysis in differentiated NPCs (after 31 days of differentiation) as measured by RT-
qPCR (n=3 biological replicas). Also shown is the p value (0.0004 and 0.0001, One-way 
ANOVA with Tukey) of the comparisons and the SEM. (B) Western-blot analyses of L1-ORF1p 
expression in the indicated cell type (above each lane). Beta actin was included as an internal 
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control. (C) Rationale of the NPC differentiation Ad-L1 retrotransposition assay. A 
representative picture of NPCs and of mature neuronal cells is shown on top. At days 0, 5, 10, 
15, 25 or 31, plated cells were infected with Ad-L1 in the presence of BrdU and analyzed 5-7 
days later. (D) Representative results from retrotransposition assays conducted in differentiating 
NPCs using the Ad-L1. Each panel shows a merged image of Ad-L1 infected NPCs analyzed 5-7 
days after infection and stained with an antibody against NES or TUBB3 (pink) and BrdU (red); 
nuclear DNA was stained with DAPI (blue) and L1-EGFP was stained with an EGFP polyclonal 
antibody (green). The left side contains the independent captured images used in the merged 
picture. White bars, 10 μm d0 panels, and 20 μm d5 and d31 panels. Also indicated in each panel 
is the day when infection was performed (white letters on DAPI panels). (E) Results from the 
PCR-intron assay conducted on gDNAs isolated from Ad-L1 infected NPCs at the indicated 
time. In the PCR assay, gDNA isolated from pk87 cells (Garcia-Perez et al. 2010) and a vector 
containing the unspliced megfpI cassette (99-gfp-LRE3) were included as controls. c- lane, PCR 
negative control without template. 
Fig. 6. Efficient LINE-1 retrotransposition in differentiating NPCs. (A) Scheme of plasmid 
99-gfp-LRE3-UB* and of DNA transfection-based experiments conducted in differentiating 
NPCs. Below is shown a representative image of differentiating NPCs transfected at day 31 in 
the presence of BrdU and stained with L1-EGFP (green), MAP2 (pink) and BrdU (red); nuclear 
DNA was stained with DAPI (blue). The left side contains the independent captured images used 
in the merged picture. A white arrow marks a MAP2/L1-EGFP single cell that stain negative for 
BrdU. White bars, 50 μm. (B) L1-EGFP copy number quantification in differentiating NPCs 
infected at the indicated time. The graph shows the normalized number of L1-EGFP sequences 
detected (L1 insertions) and has been corrected with infection efficiency values (using beta gal 
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qPCR data) and for cell proliferation values. The p value of the comparison (0.0027) and the 
SEM are also indicated. (C) Rationale of the RBFOX3 sorting-based assay. Differentiated NPCs 
(at day 31) were infected with the Ad-L1 and 5 days later RBFOX3-expressing cells were 
FACS-sorted and gDNA isolated. The right side shows representative FACS histogram plots of 
cells incubated (bottom row) or not (top row) with the anti RBFOX3 antibody. (D) Results from 
the PCR-intron assay conducted on gDNAs isolated from Ad-L1 infected NPCs at day 31 and 
FACS-sorted (using a RBFOX3 antibody) 5 days after the infection. gDNA isolated from 
unsorted infected differentiated NPCs and infected HeLa cells were used as a controls in these 
assays. C- lane, PCR negative control without template. (E) L1-EGFP copy number 
quantification in differentiated Ad-L1 infected NPCs sorted for RBFOX3 expression. The graph 
shows normalized L1 insertions (i.e., the number of L1-EGFP sequences detected) and for 
comparison the value obtained in unsorted Ad-L1 infected hESC-NPCs at day d31 post-
differentiation was designated 1. n.s., not significant. The SEM is also shown. In panels B and E, 
an unpaired Student’s t-test applied. 
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Table 1: Summary of expression and retrotransposition in somatic stem cells. The level of L1 mRNA and ORF1p expression, as well as the methylation level of 
L1Hs promoters is indicated using + and – signs; ++++, very high level; +++, high level; ++, moderate level; +, low level; -/+, very low level, near the detection limit.  
Cell line Parental cell 
Differentiation L1- 
mRNA 
Level 
L1-
ORF1p 
Level 
L1 Promoter 
Methylation 
Level 
Retrotransposition 
Protocol Markers Assay Detection Levels 
H9- hESC - 
Garcia-
Perez  et al. 
2007b 
OCT4 (+), TRA1-60 
(+), SSEA-4 (+)  ++++ ++++ + 
Plasmid 
and Ad-
L1 
FACS, PCR, 
insertion 
characterization 
++ 
hESC-NPCs hESCs Coufal et al. 2009 
Morphology, NES 
(+) ++ ++ ++ 
Plasmid 
and Ad-
L1 
FACS, PCR,  
qPCR, insertion 
characterization 
+++ 
 KER Foreskin Aasen et al. 2008 Morphology -/+ -/+ +++ 
Plasmid 
and Ad-
L1 
FACS, PCR, 
qPCR -/+ 
HFFs Foreskin  Morphology -/+ -/+ +++ 
Plasmid 
and Ad-
L1 
FACS, PCR, 
qPCR -/+ 
hESC-NPCS d31 hESC-derived NPCs 
Griesi-
Oliveira et 
al. 2014 
RBFOX 3(+), 
TUBB3 (+), MAP2 
(+), Synapsin I (+) 
+ + +++ 
Plasmid 
and Ad-
L1 
FACS, PCR, 
qPCR +++ 
MCSs 
Multiple adult 
sources and 
hESCs 
Sanchez et 
al. 2011 
NT5E(CD73) (+), 
ENG(CD105) (+),  
THY1(CD90) (+), 
ALCAM(CD166) 
(+), PTPRC(CD45) 
(-), CD34 (-), CD19 
(-), SSEA-4 (-) 
-/+ -/+ +++ 
Plasmid 
and Ad-
L1 
FACS, PCR, 
qPCR -/+ 
HSCs (CD34+ UCB) UCB Montes et al. 2011 CD34 (+) -/+ n.a +++ Ad-L1 
FACS, PCR, 
qPCR -/+ 
HSCs (hESC-CD45+ and 
hESC-CD45negPFV) hESCs 
Chadwick et 
al., 2003 
PTPRC(CD45)(+) 
and  
PECAM1(CD31) 
(+) 
-/+ n.a +++ Ad-L1 FACS, PCR, qPCR -/+ 
HSCs (hESC-
CD45negPFV) hESCs 
Choi et al., 
2011 
PECAM1(CD31) 
(+) -/+ n.a +++ Ad-L1 
FACS, PCR, 
qPCR -/+ 
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